Protein kinase CK2 is a protein serine/threonine kinase that exhibits elevated expression in a number of cancers and displays oncogenic activity in mice. The regulatory CK2b subunit has a central role in assembly of functional tetrameric CK2 complexes where it participates in modulation of catalytic activity and substrate speci®city. Since overexpression of CK2b results in elevated levels of CK2 activity, we investigated the molecular mechanisms that control its degradation since perturbations in these pathways could contribute to elevated CK2 in cancer. In this study, we demonstrate that CK2b is degraded by a proteasome-dependent pathway and that it is ubiquitinated. We have also investigated the role of phosphorylation and a putative destruction box in regulating its stability in cells. Importantly, replacement of three serine residues within the autophosphorylation site of CK2b with glutamic acid residues resulted in a signi®cant decrease in its degradation indicating that autophosphorylation is involved in regulating its stability. Notably, although the autophosphorylation site of CK2b is remarkably conserved between species, this is the ®rst functional role ascribed to this site. Furthermore, based on these results, we speculate that alterations in the phosphorylation or dephosphorylation of the regulatory CK2b subunit could underlie the elevated expression of CK2 that is observed in cancer cells.
Introduction
Protein kinase CK2 is a protein serine/threonine kinase that has been implicated in the control of various aspects of cell proliferation and transformation (Litch®eld and LuÈ scher, 1993; Allende and Allende, 1995; Pinna and Meggio, 1997; Guerra and Issinger, 1999; . Genetic studies in yeasts, worms and slime mold have demonstrated that CK2 is essential for viability (Hanna et al., 1995; Rethinaswamy et al., 1998; Kikkawa et al., 1992; Fraser et al., 2000) . More detailed investigations of CK2 in yeast and in mammalian cells have further demonstrated that CK2 is required for cell cycle progression with roles at dierent stages in the cell cycle including G1, G1/S and G2/M (Hanna et al., 1995; Pepperkok et al., 1991; Lorenz et al., 1993) . A role for CK2 in cellular responses to various stresses including UV, anisomycin, arsenite, heat shock and TNFa has also recently emerged (Sayed et al., 2000; Ghavidel and Schultz, 2001; Keller et al., 2001; Gerber et al., 2000) .
Components of stress response pathways or cell cycle regulatory pathways are frequently perturbed in cancer. Accordingly, alterations in CK2 levels have been observed in leukemic cells and in tumors. For example, increased levels of CK2 are observed in a variety of tumor cells including cancer cells derived from head and neck (Faust et al., 1996) , prostate (Yenice et al., 1994) , lung (Daya-Makin et al., 1994) , kidney (Stalter et al., 1994) and breast (LandesmanBollag et al., 2001) . Dramatic elevations in CK2 are also observed in the lymphocytes of parasite-infected cattle where the lymphocytes exhibited lymphoblastic appearance and tumor-forming ability in mice (ole-Moi Yoi et al., 1993) . A more direct link between CK2 and transformation occurs in transgenic mice with targeted over-expression of CK2a in T cells (Seldin and Leder, 1995) . These mice exhibit a striking predisposition for lymphoma development. Furthermore, CK2a exhibits oncogenic cooperatively in mice overexpressing the cMyc or Tal-1 oncogenes, and in p53-de®cient mice Kelliher et al., 1996) . Enhanced lymphoproliferation is also observed when these CK2-overexpressing mice are bred with lpr-mice that harbor mutations in the Fas receptor that confers defects in Fas-mediated apoptotic events (Rifkin et al., 1998) . In a similar vein, targeted overexpression of CK2 results in mammary gland tumorigenesis (Landesman-Bollag et al., 2001) . CK2 also collaborates with Ha-Ras in the transformation of rat embryo ®broblasts and Balb/c 3T3 ®broblasts (Orlandini et al., 1998) .
In mammals, CK2 is typically a tetrameric enzyme composed of two catalytic (CK2a CK2a' and/or CK2a'') subunits and two regulatory CK2b subunits (Litch®eld and LuÈ scher, 1993; Allende and Allende, 1995; Pinna and Meggio, 1997; Guerra and Issinger, 1999; Shi et al., 2001) . CK2b mediates formation of tetrameric CK2 complexes and appears to play a role in stabilizing the catalytic subunits of CK2 and in modulating the substrate speci®city of CK2 through its ability to regulate the catalytic subunits of CK2 and its ability to interact with cellular proteins such as p53 (Meek et al., 1990; Filhol et al., 1992; Prowald et al., 1997) .
Overexpression studies have also demonstrated that increased expression of CK2b is sucient to elevate cellular CK2 activity, presumably by increasing the amount of tetrameric CK2 that is formed (Vilk et al., 2002) . Given the importance of CK2b in regulating the functions of the catalytic CK2 subunits and its ability to induce increased CK2 activity, it is thus intriguing that alterations in the levels of CK2b relative to the levels of CK2a have also been observed in tumors (Stalter et al., 1994) .
The regulatory CK2b subunit exhibits remarkable conservation; in fact the deduced amino acid sequences of CK2b are identical in chickens and in mammals (Litch®eld and LuÈ scher, 1993; Allende and Allende, 1995) . Moreover, these sequences dier from the sequence of CK2b from Xenopus by a single amino acid and from the CK2b sequence from Zebra®sh by only two amino acids. We, and others, have previously demonstrated that CK2b is phosphorylated in cells and that the major site of phosphorylation is an autophosphorylation site consisting of serine residues located at its amino terminus (Ackerman et al., 1990; Litch®eld et al., 1991 Litch®eld et al., , 1992 . The autophosphorylation of CK2b occurs through intermolecular phosphorylation of the regulatory CK2b subunits by the catalytic subunits of CK2. Despite the conservation of these autophosphorylation sites between species, precise elucidation of their functions has remained elusive. CK2b also contains a sequence reminiscent of the destruction box that confers cell cycle dependent degradation of the mitotic cyclins (Glotzer et al., 1991; Allende and Allende, 1995; King et al., 1996; Hershko and Ciechanover, 1998) . Based on the importance of cell cycle dependent phosphorylation and/or a destruction box in regulating the degradation of various cyclins, it is intriguing to speculate that the turnover of CK2b could also be regulated by phosphorylation and/or its destruction box.
Since CK2b exerts a central role in modulating the catalytic activity of CK2, because it is overexpressed in tumors and because of its similarities with cyclins, we have been interested in investigating the mechanisms that control its turnover. In a previous biosynthetic labeling study (LuÈ scher and Litch®eld, 1994) , we demonstrated that CK2b exhibits a biphasic degradation. CK2b that fails to form complexes with catalytic CK2 subunits is rapidly degraded with a half-life of less than 1 h whereas CK2b that enters into complexes with catalytic CK2 subunits is very stable. In the present study, we demonstrate that the degradation of CK2b is inhibited by proteasome inhibitors and that CK2b is ubiquitinated in cells. Mutation of a conserved arginine residue within the putative destruction box of CK2b did not dramatically aect the degradation of CK2b indicating that the destruction box by itself is not sucient to confer instability on CK2b. By comparison, mutation of three serine residues (i.e. Ser2, Ser3, Ser4) within the autophosphorylation site on CK2b to acidic amino acids results in attenuation of its degradation.
Results

Degradation of the regulatory CK2b subunit is inhibited by proteasome inhibitors
Our previous biosynthetic labeling studies had indicated that the population of CK2b that failed to form complexes with CK2a was rapidly degraded whereas the CK2b that formed complexes with CK2a was stable (LuÈ scher and Litch®eld, 1994) . To extend these observations, chicken bursal lymphoma BK3A cells were labeled with a short pulse of 35 S-methionine and cysteine and CK2 was isolated by immunoprecipitation with anti-CK2b antibodies immediately after labeling and after a 3 h chase with unlabeled methionine and cysteine ( Figure 1 ). It is evident in Figure 1a that the amount of labeled CK2b isolated in these immunoprecipitates is signi®cantly diminished after the 3 h chase indicating that a signi®cant proportion of CK2b has been degraded. By comparison, the amount of labeled CK2a that is evident in anti-CK2b immunoprecipitates is not dramatically changed after the chase indicating that complexes containing both CK2a and CK2b have not been degraded. This observation is entirely consistent with our previous studies where we observed that approximately half of the newly synthesized CK2b was rapidly degraded with the remainder becoming incorporated into tetrameric CK2 complexes that were stable for several hours (LuÈ scher and Litch®eld, 1994) .
To determine whether the degradation of the CK2b that is observed occurs through a proteasomal pathway, the pulse-chase experiment was performed in the presence of lactacystin. As illustrated in Figure 1b , nearly 50% of the CK2b is degraded in the absence of lactacystin whereas in the presence of lactacystin approximately 90% of the CK2b is still present after the chase. It is also evident from Figure 1a that the levels of radiolabeled CK2b that are observed at time 0 in the presence of lactacystin exceed the levels of radiolabeled CK2b that are observed in the absence of lactacystin. This observation likely re¯ects the fact that lactacystin-treated cells were treated with the drug prior to and during biosynthetic labeling and during the subsequent chase. Consequently, it is likely that lactacystin would prevent any degradation of CK2b that occurs during the labeling period itself and during subsequent processing at the end of the labeling period. Notably, the degradation of CK2b was almost entirely abolished in the presence of lactacystin, a result that is consistent with degradation occurring via the proteasome (Dick et al., 1997) . As was the case in the absence of lactacystin, the levels of radiolabeled CK2a that were evident in anti-CK2b immunoprecipitates were not dramatically altered during the chase. When the data is expressed to illustrate the relative degradation of CK2b in Figure 1c , it is apparent that the amount of CK2b that was degraded was approximately fourfold Oncogene Phosphorylation regulates the stability of CK2b b C Zhang et al less in the presence of lactacystin than in its absence. Since tetrameric CK2 complexes that contain both CK2a and CK2b would not be signi®cantly degraded during the 3 h chase, it is likely that most of the residual CK2b that is seen in the absence of lactacystin after the 3 h chase exists in tetrameric CK2 complexes. Therefore, the dierence in the stability of uncomplexed CK2b in the presence of lactacystin versus the absence of lactacystin is likely to be much greater than fourfold.
To further investigate the role of the proteasome in the degradation of CK2b, we examined the ability of a proteasome inhibitor (MG132) (de Hoog et al., 2001) to aect the steady state levels of transfected CK2b that had been tagged with an N-terminal Myc epitope (Figure 2 ). Levels of Myc-CK2b, as detected by Western blotting, are signi®cantly increased by inhibition of the proteasome. By comparison, MG132 does not appear to signi®cantly aect the steady state levels of b-tubulin. Consequently, we conclude that, as was observed with endogenous CK2b, transfected MycCK2b is also degraded via the proteasome. The demonstration that the degradation of transfected CK2b and endogenous CK2b are both mediated by the proteasome is important, as it allows the use of a mutagenesis approach to investigate the participation of speci®c residues in regulating the degradation of CK2b.
CK2b is ubiquitinated in cells
Since the degradation of CK2b was inhibited by proteasome inhibitors, we were next interested in determining whether or not CK2b is ubiquitinated in cells. To address this issue, cells were cotransfected with Myc-tagged CK2b and HA-tagged ubiquitin (Figure 3 ). Anti-Myc immunoprecipitates were performed and immunoprecipitates analysed on immunoblots with anti-HA antibodies (left panel). A series of bands are readily detected when HA-ubiquitin was transfected with Myc-CK2b but not when either of the constructs were transfected alone. This result clearly suggests that Myc-CK2b had been ubiquitinated or that a number of ubiquitinated proteins are isolated in complexes with Myc-CK2b (Figure 3a ). To further examine the ubiquitination of CK2b and to determine whether it is covalently labeled with ubiquitin, cells were cotransfected with HA-tagged CK2b together with His-tagged ubiquitin (Treier et al., 1994) (right panel). Cells were extracted using guanidine, a denaturant that will disrupt non-covalent complexes between proteins. His-ubiquitin was subsequently isolated using anity chromatography with a Nickel column. Immunoblots performed with anti-HA to detect HA-CK2b clearly reveal the presence of a ladder of bands indicating that HA-CK2b had been covalently modi®ed by the addition of ubiquitin (Figure 3b ). 
Examination of the putative destruction box in CK2b
As illustrated in Figure 4a , CK2b contains a sequence that is reminiscent of the destruction box that confers instability to mitotic cyclins and other short-lived proteins (Hershko and Ciechanover, 1998; Glotzer et al., 1991; King et al., 1996) . Of particular note is the presence of an arginine at position 1 and a leucine at position 4 in the putative destruction box of CK2b that are invariant within mitotic cyclins. Mutation of the conserved arginine within a mitotic cyclin to cysteine has been shown to stabilize these proteins (Glotzer et al., 1991; King et al., 1996) . Accordingly, we performed an analagous mutation within CK2b by mutating Arg47 to cysteine, and examined the stability of this mutant, designated Myc-CK2bR47/C, relative to that of wild-type CK2b. To examine protein stability, wildtype and mutant Myc-CK2b were transiently transfected into cells. At time 0, cycloheximide was added to cells to inhibit subsequent protein synthesis for the indicated times and steady-state levels of Myc-CK2b were assessed on immunoblots with anti-CK2b antibodies ( Figure 4b ) and with anti-Myc antibodies (data not shown). As expected, since we are examining steady state levels of CK2, the levels of endogenous CK2b which are predominantly within stable CK2 complexes do not signi®cantly decrease during the cycloheximide treatment. By comparison, following a 3 h incubation in the presence of cycloheximide, a signi®cant proportion of wild-type Myc-CK2b had degraded since the majority of this material has not entered into complexes with catalytic CK2 subunits. A similar proportion of the Myc-CK2bR47/C had also degraded suggesting that the stability of this mutant had not been signi®cantly enhanced relative to that of wild-type CK2b. Similar ®ndings were obtained by the examination of Myc-CK2b or Myc-CK2bR47/C levels in pulse chase experiments where we did not observe any dramatic dierences in the degradation of MycCK2b or Myc-CK2bR47C following biosynthetic labeling with methionine/cysteine (data not shown). An examination of the stability of Myc-CK2bR47/C in nocodazole-arrested cells also failed to uncover any dierences between this mutant and wild-type MycCK2b (data not shown). These observations are in stark contrast to the ®ndings that have been published with mitotic cyclins where mutation of the arginine residues within the destruction box can nearly completely protect the protein from degradation. Overall, our data suggest that the putative destruction box of CK2b is not by itself responsible for the instability of CK2b, at least under the experimental conditions that we have employed in this study. Cells were lysed and His-Ubiquitin was isolated using Ni-NTA beads as described in Materials and methods. The presence of HA-CK2b in these isolates was examined by Western blots using anti-HA antibodies 
Examination of stability of phosphorylation-site mutants of CK2b
Whereas the degradation of mitotic cyclins requires a destruction box, the degradation of G1 cyclins such as cyclin D and cyclin E involves regulatory phosphorylation events (Yew, 2001; Koepp et al., 2001) . Phosphorylation of cyclin D by glycogen synthase kinase-3b is involved in triggering degradation of that cyclin while cell cycle dependent autophosphorylation of cyclin E is involved in its degradation (Diehl et al., 1998; Winston et al., 1999) . In contrast to the cyclins where phosphorylation signals degradation, phosphorylation of c-Mos has been demonstrated to have a stabilizing eect (Pham et al., 1999; Castro et al., 2001 ). Since CK2b is also subject to phosphorylation, we were interested in investigating the role of phosphorylation in regulating its stability. To investigate the role of the autophosphorylation sites of CK2b in regulating its stability, we generated mutants of CK2b with the autophosphorylation sites (i.e. Ser2, Ser3 and Ser4) mutated to non-phosphorylatable alanine residues or to glutamic acids that may serve as phosphomimetic residues. As illustrated in Figure 5 , the triple glutamic acid mutant exhibited enhanced stability whereas the alanine mutants exhibited stability that was not dramatically dierent from that of wild-type CK2b.
Based on the results with the triple glutamic acid mutant, it is apparent that the autophosphorylation site of CK2b has a role in modulating its stability. Moreover, since the glutamic acid mutants may be phosphomimetic, these results suggest that phosphorylation stabilizes CK2b, a conclusion that is consistent with our results. By comparison, it may be predicted that the triple alanine mutant of CK2b exhibits decreased stability as compared to wild-type CK2 since this mutant would be non-phosphorylatable. However, as illustrated in Figure 5 , our results indicate that the triple alanine mutant is not signi®cantly dierent from wild-type CK2b. This result could suggest that the triple alanine mutant is still phosphorylated at noncanonical CK2 sites that become phosphorylated when the preferred sites of phosphorylation are mutated. Alternatively, the majority of the wild-type CK2b that is destined for rapid degradation may be degraded before it can be phosphorylated (LuÈ scher and Litch®eld, 1994) . With this latter scenario, a dramatic dierence between the stability of the wild-type CK2b and the triple alanine mutant may not be expected. Consequently, to further investigate the relationship between phosphorylation and the degradation of CK2b, cells that had been transfected with wild-type Myc-CK2b were treated with apigenin or DRB, two compounds known to inhibit CK2 in cells (Ford et al., 2000; Song et al., 2000; Sayed et al., 2001) . As illustrated in Figure 6 , neither apigenin nor DRB signi®cantly aected the stability of wild-type MycCK2b. This observation is consistent with our previous studies (LuÈ scher and Litch®eld, 1994 ) that demonstrated much of the newly synthesized CK2b is degraded before it is phosphorylated. Furthermore, this observation is entirely consistent with the results illustrated in Figure 5 that demonstrate that wild-type CK2b and the triple alanine mutant of CK2b display similar stability. Nevertheless, the fact that CK2b can be phosphorylated by CK2 at multiple serines within its autophosphorylation site and that it can be phosphorylated by at least one other protein kinase at a site distinct from the autophosphorylation site (Litch®eld et al., 1991) suggests that elucidation of the precise role of individual phosphorylation sites in regulating the stability of CK2b may be very complex. Importantly, the enhanced stability of the triple glutamic acid mutant of CK2b indicates that the autophosphorylation site of CK2b does regulate its stability.
The experiments that are illustrated in Figure 5 were performed in asynchronous cells. When the triple Figure 5 The autophosphorylation site of CK2b regulates its degradation. (a) Examination of stability of wild-type Myc-CK2b or autophosphorylation site mutants of Myc-CK2b. Ser2, Ser3 and Ser4 within the autophosphorylation site of CK2 were mutated to non-phosphorylatable alanine residues (SSS/AAA) or to phosphomimetic glutamic acid residues (SSS/EEE). Human osteosarcoma U2-OS cells were transfected with the appropriate constructs. At time 0, cycloheximide was added to inhibit protein synthesis. Myc-CK2b levels were examined prior to addition of cycloheximide (i.e. time 0) and after 3 h on immunoblots using anti-CK2b 198 ± 215 antibodies that detect endogenous CK2b and Myc-tagged proteins. Immune complexes were detected with I 125 -protein A and examined with a phosphorimager. (b) Graphical representation illustrating the percentages of Myc-CK2b or autophosphorylation site mutants of Myc-CK2b that remain after a 3 h treatment with cycloheximide as determined by quantitation with a phosphorimager. (c) Graphical representation illustrating the relative levels of Myc-CK2b degradation that occurred during the 3 h treatment with cycloheximide as determined by quantitation using a phosphorimager. Values illustrated represent average+s.d. for nine independent measurements. *P value50.001 for wild-type Myc-CK2b versus the SSS/ EEE mutant of Myc-CK2b
Phosphorylation regulates the stability of CK2b b C Zhang et al glutamic acid mutant was examined in nocodazolearrested cells, no further eect on stability was observed (data not shown). Combination mutants consisting of the autophosphorylation site mutants together with mutation of the conserved arginine within the putative destruction box of CK2b exhibited similar stability to that of the autophosphorylation site mutants alone (Figure 7 ). These results con®rm that the autophosphorylation of CK2b is involved in regulating its stability. However, it does not appear that the destruction box has any role in modulating the stability of CK2b at least in the context of the autophosphorylation of CK2.
Discussion
The results presented in this paper demonstrate that the regulatory CK2b subunit is ubiquitinated in mammalian cells and that its degradation is mediated by the proteasome. Our data also indicate that phosphorylation sites on CK2b participate in the regulation of its turnover since phosphorylation site mutants of CK2b exhibit altered stability as compared to wild-type CK2b. Mutation of the autophosphorylation sites of CK2b to glutamic acid results in a marked stabilization of the protein that is not observed when these sites are converted to alanine residues. Since glutamic acids may be phosphomimetic, these results suggest that phosphorylation of the autophosphorylation sites on CK2b is a signal that stabilizes the protein. Consistent with this conclusion is the failure of the alanine mutants of CK2b to enhance CK2b stability. This demonstration that mutation of the autophosphorylation site of CK2b has functional consequences represents the ®rst indication for a regulatory role of the autophosphorylation sites of CK2 in cells. In fact, despite the remarkable conserva- tion of these autophosphorylation sites between species, a precise understanding of its functions has remained elusive. Prior to this study, the only potential functional eect of autophosphorylation was a modest (*30%) eect on the catalytic activity of CK2 when examined in vitro (Lin et al., 1994; Bodenbach et al., 1994) . The relationship of this latter observation to the physiological functions or regulation of CK2 in cells was not investigated.
Although the experiments that are reported here are restricted to an investigation of CK2b, it is noteworthy that the results presented in this paper are analogous to other studies reporting on a protective or stabilizing role for CK2 catalyzed phosphorylation. For example, the recent study of Song et al. (2000) demonstrates that CK2 inhibitors block phosphorylation of b-catenin and decrease its stability indicating that CK2 catalyzed phosphorylation of b-catenin protects it from proteasomal degradation. In a somewhat related vein, phosphorylation by CK2 has also been shown to protect proteins such as Max and Bid from caspasedependent degradation (Krippner-Heidenreich et al., 2001; Desagher et al., 2001) . Given the importance of proteins such as b-catenin, Max and Bid in the control of proliferation and apoptosis, it is tempting to speculate that some of the transforming properties of CK2 could relate to its ability to regulate the stability of important cellular regulators.
The demonstration that the autophosphorylation sites of CK2b has functional consequences within cells provides a basis for understanding why this site is so highly conserved between species (Litch®eld and LuÈ scher, 1993; Allende and Allende, 1995) . However, there are a number of unresolved questions regarding the autophosphorylation of CK2 that are beyond the scope of the present investigation. The conventional view of CK2 is that catalytic and regulatory subunits of CK2 assemble into stable tetrameric complexes and that autophosphorylation occurs following complex assembly (LuÈ scher and Litch®eld, 1994; Graham and Litch®eld, 2000; Canton et al., 2001) . With this conventional view, it might be therefore predicted that autophosphorylated CK2b only exists within tetrameric CK2 complexes. However, a mounting body of evidence indicates that CK2b has functions that are independent of its role in CK2 complexes (Boldyre and Issinger, 1997; Li et al., 1999; Toczyski et al., 1997; Teitz et al., 1990) . The three-dimensional structure of tetrameric CK2 that has emerged from X-ray crystallography also challenges the traditional view that CK2 complexes are stable tetramers (Nie®nd et al., 2001) . In particular, calculations of the surface contacts that exist between catalytic and regulatory CK2 subunits are not consistent with a model where complexes between catalytic and regulatory CK2 subunits are irreversible. In fact, the limited area involved in surface contacts between catalytic and regulatory CK2 subunits suggests that there is a reasonable likelihood that CK2 complexes are subject to dissociation. Molecular imaging approaches for a thorough investigation of the dynamic localization of the individual CK2 subunits will be required to de®nitively resolve this issue and to determine to what extent, if any, CK2 complexes are subject to disassembly and re-assembly.
On the basis of its close similarity to the destruction box found within mitotic cyclins (Hershko and Ciechanover, 1998; Glotzer et al., 1991; King et al., 1996) , it is perhaps somewhat surprising that mutation of the putative destruction box of CK2b was without a dramatic eect on the stability of CK2b. However, CK2 is believed to participate in a complex series of cellular functions and to localize to a number of distinct cellular sites. Therefore, we cannot exclude the possibility that this sequence is involved in the degradation of a speci®c sub-population of CK2b perhaps even at a speci®c stage within the cell cycle or in response to a speci®c signal that was not examined in this study. For example, CK2b has been shown to localize within the cytoplasm and in the nucleus as well as with speci®c cellular structures such as centrosomes (Yu et al., 1991; Krek et al., 1992; Faust and Montenarh, 2000) . Since the proportion of CK2 that would be associated with speci®c cellular structures would be a small fraction of the total cellular CK2, alterations in the stability of such a fraction of CK2 could be readily overlooked.
Alternatively, the putative destruction box of CK2b may lack residues that are required for functionality. As illustrated in Figure 4 , CK2b does indeed contain residues such as an arginine in position 1 and a leucine in position 4 that match the destruction box consensus. By comparison, CK2b contains an aspartic acid in position 9 instead of an asparagine residue that predominates within the sequence of mitotic B cyclins. In fact, in a systematic study of dierent destruction box sequences, King et al. (1996) demonstrated that fusion proteins containing a destruction box were stabilized when the asparagine at position 9 was replaced with aspartic acid. The presence of this sequence within CK2b may re¯ect common ancestral origins between CK2b and the cyclins. Indeed, there are striking similarities between CK2b and the cyclins. In particular, CK2b and cyclins are regulatory subunits for protein kinases. It may also be noteworthy that the catalytic subunits of CK2 and the cyclin-dependent kinases are rather closely related on the phylogenetic trees of the protein serine/threonine kinase families (Hanks and Hunter, 1995) . Like cyclins, our data in this paper indicate that CK2b is also targeted for polyubiquitination and degradation via a proteasomemediated pathway. However, unlike cyclins, CK2b appears to be expressed at all stages in the cell cycle (Bosc et al., 1999) . Also, on the basis of the studies described here, it is not evident that the putative destruction box of CK2b is functionally related to its degradation.
The regulatory CK2b subunit plays an important role in regulating the catalytic activity, stability and substrate speci®city of CK2. As noted earlier, in addition to its role as a subunit of CK2, there is a growing body of information to suggest that CK2b has Phosphorylation regulates the stability of CK2b b C Zhang et al functions that are independent of the CK2 complex. For example, CK2b interacts with other cellular proteins including protein kinases such as A-Raf and c-Mos and the p53 tumor suppressor (Meek et al., 1990; Filhol et al., 1992; Prowald et al., 1997) . CK2b stimulates A-Raf kinase activity and is an inhibitor of the kinase activity of c-Mos. Increased expression of CK2b in Xenopus oocytes inhibits maturation presumably through inhibition of c-Mos . Given its important role in regulating the cellular functions of CK2 and its potential for participating in other aspects of cellular regulation, it is clearly important to de®ne how the turnover of CK2b is regulated in mammalian cells. An understanding of how cellular levels of CK2b are regulated in cells may have relevance to the overexpression of CK2 that is frequently observed in cancer cells and to the oncogenic activity that is exhibited by CK2. Since the overexpression of CK2b can result in increased levels of CK2 activity within cells, it is tempting to speculate that defects in the normal degradation of CK2b could contribute to the increased CK2 activity that is observed in cancer cells. Such a mechanism for increased expression of CK2b would be in keeping with the recent demonstration that the degradative machinery responsible for regulating cyclin E levels is indeed perturbed in cancer cells (Schwab and Tyers, 2001; Moberg et al., 2001; Strohmaier et al., 2001) . In this regard, the alterations in the relative ratios of catalytic and regulatory subunits of CK2 that are observed in cancer cells are especially intriguing (Stalter et al., 1994) . In this study, we have demonstrated that CK2b is ubiquitinated and degraded via the proteasome and that autophosphorylation has a role in regulating its turnover. In the future, it will be of interest to investigate these events in cancer cells to determine whether alterations in these events underlie the dysregulated expression of CK2 that is observed in many forms of cancer.
Materials and methods
Plasmid constructs
Constructs encoding Myc-tagged CK2b and HA-tagged CK2b were previously described . Mutations, including autophosphorylation site mutants and the R47/C mutation within the putative destruction box of CK2b were generated using the polymerase chain reaction (Canton et al., 2001) . For the R47/C mutation, a portion of CK2b was ampli®ed with a forward primer containing the mutation and a PpuM1 site (5'-CAG GTC CCT CAC TAT TGC CAA GCT CTA GAC AT-3') and a reverse primer containing the 3' end of the coding region of CK2b and a BamHI site (CGG GGG ATC CAG ACT GCA GGA CAG GTG-3'). The ampli®ed fragment was subcloned into the PCR2.1 vector (Invitrogen) where it was sequenced. Plasmids with the correct inset were digested with PpuM1 and ApaI and the corresponding PpuM1/ApaI fragment was subcloned into the appropriate PpuM1 and ApaI sites of pRc/CMV-HA/CK2b or pRc/CMV-Myc/CK2b. Replacement of Ser2, Ser3 and Ser4 in the autophosphorylation site of CK2b with glutamic acid residues (i.e. SSS/EEE) or with alanine (i.e. SSS/AAA) was achieved by two step PCR using the proofreading polymerase Pfu (Stratagene). In the ®rst round, two PCR products were generated for each construct using pRc/CMV-Myc/CK2b as the template. The following primers were used for the SSS/EEE construct: 5' GAA GAT GGA AGA GGA AGA GGA GGT GTC CTG GAT TTC-3' (forward) with SP6 primer as the reverse primer (5'-GAT TTA GGT GAC ACT ATA G-3') as well as the T7 primer (TAA TAC GAC TCA CTA TAG GG) as the forward primer together with 5'-CTT CTT CCT CTT CCA TCT TCA CGT CAG CGG CTG-3') as the reverse primer. The PCR products were gel puri®ed, denatured and annealed to each other to primer the second round of PCR using T7 and SP6 primers. These products were subcloned into PCR-Blunt (Invitrogen) and veri®ed by DNA sequencing prior to subcloning into the NotI and ApaI sites of pRc/CMV. The same strategy was utilized for the SSS/AAA construct with the exception that the primer 5'-GAA GAT GGC TGC GGC AGA GGA GGT GTC CTG GAT T-3' was used in combination with the SP6 primer and 5'-CCT CTG CCG CAG CCA TCT TCA CGT CAG CGG CTG-3' was used in combination with the T7 primer.
Combination mutants (i.e. autophosphorylation site together with the R47/C mutation) were generated by swapping a PpuM1/ApaI fragment containing the R47/C mutation between the respective constructs. Constructs encoding Histagged ubiquitin (pMT107) and HA-tagged ubiquitin (pMT123) were a generous gift from Dr D Bohmann (Treier et al., 1994; Musti et al., 1997) .
Cell culture, cell labeling and transfection
The chicken bursal lymphoma cell line BK3A, human osteosarcoma U2-OS cells and green monkey kidney Cos 7 cells have been described previously (LuÈ scher and Litch®eld, 1994; Graham and Litch®eld, 2000; Vilk et al., 1999) . All cells were grown at 378C in an atmosphere of 5% CO 2 . For metabolic labeling of BK3A, 2610 6 cells were labeled as described for 5 min with 0.1 mCi of 35 S-Methionine and Cysteine (EXPRESS Label from New England Nuclear). Where indicated, the proteasome inhibitor lactacystin (Calbiochem) was added to cells at a concentration of 20 mM for 2 h prior to labeling and was maintained in the culture medium during labeling and the subsequent chase. Treatment of unlabeled cells with the proteasome inhibitor MG132 (Calbiochem) at a concentration of 20 mM was performed for periods up to 5 h as indicated. Cycloheximide was added to cultures in ethanol to a ®nal concentration of 100 mg/ml for the indicated length of time (Maki and Howley, 1997) . Where indicated, cells were treated with 80 mM apigenin or 80 mM 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole (DRB) for 2 h prior to cycloheximide treatment (Sayed et al., 2001; Song et al., 2000) . Treatment with these compounds was continued for the duration of the cycloheximide treatment. Alternatively, CK2 inhibitors were removed at the time of cycloheximide addition, a manipulation that did not aect the stability of Myc-CK2b.
Transfections were performed using the calcium phosphate procedure (Penner et al., 1997) . Cells were incubated overnight with the DNA precipitate. Following thorough washing to remove the precipitate, cells were incubated for approximately 40 h before initiating an examination of protein turnover. Transfection eciency, typically in the range of 20 ± 50%, was monitored using cotransfection with pEGFP (Clontech) as a marker to ensure that transfection Oncogene Phosphorylation regulates the stability of CK2b b C Zhang et al eciency with dierent constructs was approximately equivalent.
Ubiquitination of CK2b in cells
Cos 7 cells were transfected using the calcium phosphate procedure using pRc/CMV-Myc-CK2b or pRc/CMV-HACK2b together with pMT123 (HA-ubiquitin) or pMT107 (His-ubiquitin), respectively (Treier et al., 1994; Musti et al., 1997) . Complexes containing His-ubiquitin were isolated by modi®cation of previous methods. Brie¯y, cells were lysed by the addition of 8 M guanidine-HCl, 5 mM imidazole, 0.1 M sodium phosphate, pH 8.0 followed by sonication for 4630 s bursts. The sonicate was subjected to centrifugation at 13 000 g for 15 min and 0.1 ml of a 50% slurry of Ni-NTA resin (Qiagen) equilibrated in 6 M guanidine-HCl, 0.1 M sodium phosphate, pH 8.0 was added. After incubation for 1 h at room temperature, the resin was collected by centrifugation and then washed twice with 6 M guanidineHCl, 4 mM imidazole, 0.1 M sodium phosphate, pH 8.0, twice with 8 M urea, 7 mM imidazole, 0.1 M sodium phosphate, pH 6.3 and then twice with 50 mM sodium phosphate, pH 8, 100 mM KCl, 20% glycerol, 0.2% NP-40, 7 mM imidazole. After the ®nal wash, proteins were eluted by the addition of Laemmli sample buer.
Alternatively, complexes containing Myc-CK2b were isolated by immunoprecipitation as described below using 9E10 monoclonal anti-Myc antibodies (obtained from the Developmental Studies Hybridoma Bank at the University of Iowa, IA, USA). Protein complexes isolated on Ni-NTA resin or by immunoprecipitation were subjected to electrophoresis and analysed by immunoblotting using anti-HA antibodies as described below.
Immunoprecipitation and immunoblotting
For immunoprecipitation of proteins from 35 S-labeled cells or from unlabeled cells, cells were lysed with L buer (PBS with 1% sodium deoxycholate, 1% NP-40, 50 mM b-glycerophosphate) supplemented with protease inhibitors (1 mg/ml leupeptin, 1% aprotinin, 0.1 mM phenylmethylsulfonyl¯uor-ide) as previously described (LuÈ scher and Litch®eld, 1994) . When cells were treated with MG-132, the lysis buer was supplemented with 5 mM N-ethylmaleimide. AntiCK2b 198 ± 215 antibodies were used to isolate endogenous and tagged CK2b whereas anti-Myc 9E10 monoclonal antibodies were used to isolate Myc-CK2b. Myc-tagged proteins were also detected with the same antibodies on immunoblots. HA-tagged proteins were detected with biotinylated anti-HA 3F10 rat monoclonal antibodies (Roche Biochemicals) using enhanced chemiluminescence (Supersignal from Pierce Chemical Company) as described Bosc et al., 2000) . Anti-b-tubulin (a generous gift from Dr L Dagnino, London, Canada) was utilized as a loading control for immunoblot analysis of extracts prepared from cells treated with the proteasome inhibitor MG132. CK2b and epitope-tagged CK2b were also detected with anti-CK2b 198 ± 215 antibodies. For quantitative measurement of Myc-CK2b levels, immunoblots were developed with 125 I-protein A (low speci®c activity from New England Nuclear). For these experiments, 125 I was used at a concentration of approximately 400 000 c.p.m./ml. Immune-complexes were detected and quanti®ed using a phosphorimager. Each sample was run on at least two, and in most cases three, separate gels.
As a measure of CK2b degradation, the amount of CK2b that remained following the chase or following treatment in the presence of cycloheximide was expressed as the percentage that remained following the chase and/or as relative degradation that re¯ected the proportion of CK2b that degraded during the chase. For these analyses, the amount of CK2b that was observed at time 0 was considered to be 100%. The percentage remaining re¯ects the ratio of the amount of CK2b at 3 h divided by the amount of CK2b at time 0. The relative degradation re¯ects the amount of CK2b that was lost (i.e. CK2b at time 0 minus CK2b at time 3 h) divided by the amount of CK2b at time 0. P values were determined using the Student's t-test using a two-tailed distribution.
